Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2323-2335

  Seddon, Beatrice M ^a   Maxwell, Ross J ^b   Honess, Davina J ^b   Grimshaw, Rachel ^a   Raynaud, Florence ^a   Tozer, Gillian M ^b   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Gray Cancer Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE DERIVATIVE; BIOLOGICAL MARKER; CARBOGEN; CARBON DIOXIDE; COMBRETASTATIN A4; DRUG METABOLITE; FLUORINE; HYDRALAZINE; NICOTINAMIDE; OXYGEN; PIMONIDAZOLE; DIAGNOSTIC AGENT; NITROIMIDAZOLE DERIVATIVE; TUMOR MARKER;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOSARCOMA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG RETENTION; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN TISSUE LEVEL; POLAROGRAPHY; PRIORITY JOURNAL; REDUCTION; SCID MOUSE; TUMOR XENOGRAFT; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS; ANIMAL; ANOXIA; CANCER TRANSPLANTATION; DRUG SCREENING; EXPERIMENTAL NEOPLASM; METABOLISM; METHODOLOGY; MOUSE MUTANT; RAT; TISSUE DISTRIBUTION; VALIDATION STUDY;

ANIMAL; ANOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; FEMALE; FLUORINE RADIOISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; OXYGEN; POLAROGRAPHY; RATS; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL; ANIMALS;

EID: 0035992408     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3, 3, 3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia
2. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3, 3, 3-trifluoropropyl)-2-(2- nitro-1-imidazolyl) acetamide (SR-4554, CRC 94/17): A non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography
3. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
4. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
5. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome
6. Oxygenation predicts radiation response and survival in patients with cervix cancer
7. Association between tumor hypoxia and malignant progression in advanced cancer of the cervix
8. Hypoxia in human soft tissue sarcoma is associated with poor survival
9. A confirmatory prognostic study on oxygenation status and locoregional control in advanced head and neck squamous cell carcinoma treated by radiation therapy
10. Activation of the HIF pathway in cancer
11. HIF-1 and mechanisms of hypoxia-sensing
12. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
13. Hypoxia, clonal selection, and the role of HIF- 1 in tumor progression
14. Modification of hypoxia-induced radioresistance in tumors by use of oxygen and sensitizers
15. Bioreductive drugs into the next millennium
16. Targeting tumor vasculature: The development of combretastatin A-4
17. Current status of anti-angiogenesis agents in cancer
18. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms
19. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors
20. Detection of hypoxic cells by monoclonal antibody recognising 2-nitroimidazole adducts
21. Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime
22. Imaging in hypoxia in human tumors with F-18 fluoromisonidazole
23. 123I-iodoazomycin arabinoside: Preliminary report of a clinical study
24. 19F magnetic resonance spectroscopy in vivo
25. 19F magnetic resonance spectroscopy
26. Development and validation of a solid-phase extraction and high performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR 4554) in Balb/c mouse plasma
27. The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554
28. Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3, 3, 3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554)
29. The relationship between tumor oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554
30. Measurement of tumor oxygenation: In vivo comparison of a luminescence fibre-optic sensor and a polarographic electrode in the P22 tumor
31. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer
32. Oxygen tension measurements of tumors growing in mice
33. Pancreatic tumors show high levels of hypoxia
34. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: Relationships to pretreatment tumor oxygenation and vascularisation
35. Antineoplastic agents 389. New. Synthesis of the combretastatin A-4 prodrug
36. Modification of tumor blood flow using the hypertensive agent, angiotensin II
37. United Kingdom Co-ordinating Committee on Cancer Research Guidelines for the Welfare of Animals in Experimental Neoplasia
38. Comparisons among pimonidazole binding, oxygen electrode measurements and radiation response in C3H mouse tumors
39. Effects of localised tumor hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice
40. Comparative effects of hydralazine on perfusion of KHT tumor, kidney and liver and on renal function in mice
41. Relationship of hypoxia to metallothionein expression in murine tumors
42. Accurate quantification of in vivo 3 I-P NMR signals using the variable projection method and prior knowledge
43. MRUI: A graphical user interface for accurate routine MRS data analysis
44. 1. A scheme for analysis of in vivo metabolites
45. Reducing acute and chronic hypoxia in tumors by combining nicotinamide with carbogen breathing
46. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: Effects of carbogen and nicotinamide
47. Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure
48. Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumors
49. Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models
50. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vasculature targeting activity in vivo
51. Combretastatinn- A-4, an agent that displays potent and selective toxicity toward tumor vasculature
52. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
53. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors
54. 2-histography
55. 2 tension measurements
56. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxic marker
57. Effect of injectable or inhalational anaesthetics and neuroleptic, neuroleptanalgesic, and sedative agents on tumor blood flow
58. 2 measurement in mice: Effect of tumor type, site of implantation, and anaesthesia
59. Pimonidazole: A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma
60. Biochemistry of reduction of nitroheterocycles
61. Pharmacology and toxicology of sensitisers: Mechanism studies
62. The use of nitroaromatic compounds as hypoxic cell radiosensitisers
63. 2-Hydroxylaminoimidazoles-unstable intermediates in the reduction of 2-nitroimidazoles
64. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules
65. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole
66. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells
67. Regioselective formation of a misonidazole-glutathione conjugate as a function of pH during chemical reduction
68. Misonidazole-glutathione conjugates in CHO cells
69. Reductive fragmentation of 2-nitroimidazoles: Amines and aldehydes
70. Modification of guanine derivatives by reduced 2-nitroimidazoles
71. Effects of the interaction between carbogen and nicotinamide on R3230 Ac tumor blood flow in Fischer 344 rats
72. A comparison in individual murine tumors of techniques for measuring oxygen levels
73. 3H]misonidazole binding and paired survival assay
74. Phase I pharmacokinetic and magnetic resonance spectroscopic study of the non-invasive hypoxia probe SR-4554